

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

3					
Ñ	APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
, –	09/369,236	08/04/1999	GRANT A. KRAFFT	97002-C	6514
	20306 7	7590 04/07/2003			
	MCDONNELL BOEHNEN HULBERT & BERGHOFF			EXAMINER	
	SUITE 3200	VACKER DRIVE		GUPTA, ANISH	
	CHICAGO, IL	. 00000		ART UNIT	PAPER NUMBER
				1654 DATE MAILED: 04/07/2003	12

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)				
	Office Action Comments	09/369,236	KRAFFT ET AL.				
	Office Action Summary	Examiner	Art Unit				
		Anish Gupta	1654				
	The MAILING DATE of this communication appears on the cover she it with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status							
1)⊠	Responsive to communication(s) filed on 24 D	<u> Pecember 2002</u> .					
2a)⊠	This action is FINAL . 2b) ☐ Thi	s action is non-final.					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213. Disposition of Claims							
·	Claim(s) <u>1-3,11,45 and 46</u> is/are pending in the	a annlication					
	4a) Of the above claim(s) is/are withdraw	• •					
	Claim(s) is/are allowed.	in nom consideration.					
	6) ☐ Claim(s) <u>1-3,11,45 and 46</u> is/are rejected.						
	Claim(s) is/are objected to.						
·	Claim(s) are subject to restriction and/or	election requirement					
	on Papers	cicolon requirement.					
9) The specification is objected to by the Examiner.							
·	10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.							
If approved, corrected drawings are required in reply to this Office action.							
12)☐ The oath or declaration is objected to by the Examiner.							
Priority u	ınder 35 U.S.C. §§ 119 and 120						
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).							
a)[☐ All b)☐ Some * c)☐ None of:						
	1. Certified copies of the priority documents	have been received.	·				
	2. Certified copies of the priority documents	have been received in Application	on No				
	 Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
	14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).						
a)	$$ a) \square The translation of the foreign language provisional application has been received.						
15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.							
Attachment		∆ □ 1	(PTO 440) P				
2) 🔲 Notice	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Informal Pa	(PTO-413) Paper No(s) atent Application (PTO-152)				

Serial Number: 09/369,236 Page 2

Art Unit: 1654

DETAILED ACTION

The amendment filed 12-24-02 is acknowledged. Claims 4-10 and 1-44 were canceled, claims 1-2 were amended and claims 45-46 were added. Claims 1-3, 11 and 45-46 are pending in this application.

Claim Rejections - 35 USC § 112

- 1. The rejection of claims 1-14, which were rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention, is hereby withdrawn.
- 2. The rejection of claims 1-14, which were rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for amyloid β (1-42), does not reasonably provide enablement for any amyloid β protein to form a non-fibrillar product. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to enable the invention commensurate in scope with these claims, is hereby withdrawn.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless --

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Serial Number: 09/369,236

Art Unit: 1654

- 3. The rejection of claims 1-2, 4, 6, 7-14, which were rejected under 35 U.S.C. 102(b) as being anticipated by Levine, is hereby withdrawn in view of Applicants amendment.
- 4. The rejection of claims 1-2, 7, 11, 13-14, which were rejected under 35 U.S.C. 102(b) as being anticipated by Roher et al., is hereby withdrawn in view of Applicants amendment.
- 5. Claims 1-3 and 11 remain and new claims 45-46 are rejected under 35 U.S.C. 102(b) as being anticipated by Kuo et al.

The claims are drawn to non fibrillar amyloid β proteins.

Applicants argue that the claims have been amended thereby rendering the rejection moot.

However, even with the amended claims, the prior art anticipates the claimed invention. The claims have been amended to recite that the claimed proteins have 13 to 24 amyloid β 1-42 proteins. Dependent claims state that the molecular weight of this isolated oligomeric structure is between 36 and 108kDa (see claim 3). As indicated in the previous office action, the reference discloses oligomeric structures that have a molecular weight greater than 100kDa. Specifically, sample table III of the reference discloses numerous samples that have A β N1-42, in combination with A β N1-40, which are soluble and have a molecular weight great than 100kDa (see page 4080, table III). The reference also discloses water soluble proteins that have a molecular weight of between 100kDa and 30kDa. Note that these disclosed molecular weight are well within the range claimed in claim 3 of the instant application. Moreover, the reference discloses that the these molecular weight fractions were ocatmeric or larger (see page 4080, left column). Since the

Serial Number: 09/369,236

^a Art Unit: 1654

reference discloses water soluble amlyoid β N-42 having a polymeric structure, that are octameric or larger, and have a molecular weight within the range that is claimed, the reference anticipates the claimed invention. As a final note, it is acknowledged that the reference discloses the a ratio of $A\beta$ N1-42 and AB N-40. This still reads on the claimed invention since the claims allows for any amyloid oligomeric structure so long as A β N-42 is present. Further, the reference discloses oligomer which have a much larger ratio of A β N-42 than A β N-40, for example 5 and 8 disclosed in table III.

The rejection is maintained.

. Although the reference does not teach the specific molecular weight and size of the structures, since the reference teaches up to octameric structures, oligomeric structures with the specific molecular weight and diameter size would necessarily be isolated. Therefore, the reference anticipates the claims.

Double Patenting

The rejection of Claims 1-14, which were rejected under the judicially created doctrine of 6. obviousness-type double patenting as being unpatentable over claims 1-6 of U.S. Patent No. 6,218,506. Although the conflicting claims are not identical, they are not patentably distinct from each other because of the following reasons, is hereby withdrawn in view of Applicants amendment.

Serial Number: 09/369,236

Art Unit: 1654

7. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL.** See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

() 1 (| 3/ 6).

The state of the state of the state of

8. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Anish Gupta whose telephone number is (703) 308-4001. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Brenda Brumback, can normally be reached on (703)306-3220. The fax phone number of this group is (703) 308-4242.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

BRENDA SLIDERMISORY F

SUPERVISORY PATENT EXAMINE TECHNOLOGY CENTER 16(8)